Leo Wealth LLC Grows Position in Pfizer Inc. $PFE

Leo Wealth LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 25.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 135,861 shares of the biopharmaceutical company’s stock after purchasing an additional 27,559 shares during the quarter. Leo Wealth LLC’s holdings in Pfizer were worth $3,383,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Fiduciary Alliance LLC raised its holdings in Pfizer by 46.4% in the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock worth $3,701,000 after acquiring an additional 46,043 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of Pfizer in the 3rd quarter worth $3,019,000. Vista Investment Partners LLC increased its holdings in shares of Pfizer by 236.1% in the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock worth $1,774,000 after purchasing an additional 48,900 shares in the last quarter. Money Concepts Capital Corp raised its stake in shares of Pfizer by 29.9% in the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock worth $6,325,000 after purchasing an additional 57,188 shares during the last quarter. Finally, Kepler Cheuvreux Suisse SA bought a new position in shares of Pfizer during the third quarter valued at $16,613,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.2%

Shares of Pfizer stock opened at $28.37 on Monday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $28.75. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The company has a market capitalization of $161.29 billion, a P/E ratio of 20.86 and a beta of 0.43. The company has a fifty day moving average of $27.09 and a 200 day moving average of $25.84.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period last year, the firm earned $0.63 earnings per share. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on PFE shares. Wolfe Research set a $24.00 price objective on Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. HSBC upped their target price on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a report on Monday, March 2nd. Finally, Barclays started coverage on shares of Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $28.19.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.